Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Pharma (IGC) over the last 13 years, with Q3 2025 value amounting to $93000.0.

  • Pharma's Change in Accured Expenses fell 7056.96% to $93000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 34405.01%. This contributed to the annual value of -$196000.0 for FY2025, which is 19949.24% down from last year.
  • Latest data reveals that Pharma reported Change in Accured Expenses of $93000.0 as of Q3 2025, which was down 7056.96% from -$599000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Change in Accured Expenses peaked at $484000.0 during Q1 2023, and registered a low of -$599000.0 during Q2 2025.
  • Over the past 4 years, Pharma's median Change in Accured Expenses value was $59500.0 (recorded in 2021), while the average stood at -$3714.3.
  • As far as peak fluctuations go, Pharma's Change in Accured Expenses soared by 23617.02% in 2024, and later crashed by 49668.87% in 2025.
  • Quarter analysis of 4 years shows Pharma's Change in Accured Expenses stood at -$30000.0 in 2021, then crashed by 793.33% to -$268000.0 in 2023, then grew by 19.4% to -$216000.0 in 2024, then soared by 143.06% to $93000.0 in 2025.
  • Its last three reported values are $93000.0 in Q3 2025, -$599000.0 for Q2 2025, and -$447000.0 during Q1 2025.